Abstract
Effect of lipid-lowering drugs on essential fatty acid metabolism in hyperlipidemic coronary patients: P. Salen, M. de Lorgeril, P. Boucher, A. Geyssant and JJ. Vallon, Faculté de Médecine J. Lisfranc, Saint-Etienne and Hôpital Herriot, Lyon, France
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
